Get the Daily Brief
Latest Biotech News
NGS Analytics Firm Aspect Analytics Raises €10.7 Million Series A
Belgian bioinformatics startup Aspect Analytics closed a €10 million ($11.7 million) Series A round led by PMV and Capricorn Partners to expand its cloud-based Weave platform. The platform...
NRG Therapeutics Secures £50 Million to Advance Mitochondrial Therapy in ALS
NRG Therapeutics Ltd., backed by investors including Merck KGaA and Novartis, completed an oversubscribed £50 million (US$67 million) Series B financing. The company plans to progress its novel...
BioAtla Secures FDA Meeting Outcomes for Ozuriftamab Vedotin in OPSCC
BioAtla announced results from its FDA Type B (End of Phase 2) meeting regarding the clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma. The productive...
David Baltimore’s Legacy: Nobel Laureate Passes at 87
David Baltimore, a towering figure in molecular biology and a Nobel laureate, has passed away at age 87. Renowned for his discovery of reverse transcriptase—a key enzyme in the replication of...
Rapport Therapeutics’ Seizure Drug RAP-219 Drives Stock Surge
Rapport Therapeutics announced promising mid-stage Phase 2a trial results for RAP-219, a novel drug targeting focal onset seizures. The open-label study demonstrated a median 78% reduction in...
Lilly Opens AI Drug Discovery Models to Biotech via TuneLab
Eli Lilly unveiled TuneLab, an AI platform granting select small biotech firms access to advanced drug discovery models developed from decades of Lilly's research data. The initiative aims to...
Novartis to Acquire Tourmaline Bio’s Cardiovascular Asset for $1.4B
Novartis announced a $1.4 billion agreement to acquire Tourmaline Bio, gaining rights to a promising cardiovascular therapy originally developed at Pfizer. This acquisition aims to bolster...
Breakthroughs at Lung Cancer Conferences Showcase Therapy Advances
Recent presentations at major lung cancer conferences highlighted multiple therapeutic advances for non-small cell and small cell lung cancer (NSCLC, SCLC). Among key findings, a Phase 2 study...
Novel Cancer Therapeutics: ADCs, Bottlebrush Prodrugs, and Glioblastoma Insights
Innovations in targeted cancer therapies are gaining momentum with major advancements reported in antibody-drug conjugates (ADCs) and novel prodrug designs. Research published on...
Emerging Gene and Cell Therapy Collaborations and Funding Rounds
Recent funding and strategic partnerships spotlight accelerated progress in gene and cell therapy. Epigenic Therapeutics secured $60 million in Series B financing to propel CRISPR epigenetic...
Advances in AI and Computational Methods Transform Biotech Research
Artificial intelligence is rapidly reshaping biotechnology, as demonstrated by new models and tools accelerating drug discovery and cellular analysis. A public AI model from MIT predicts long-term...
Fragile X Syndrome Candidate Acquisition Signals Neurology Pipeline Growth
Servier announced acquisition of KER-0193, an oral small molecule modulator targeting Fragile X syndrome (FXS) from UK biotech Kaerus Bioscience for up to $450 million. The move bolsters Servier’s...
Rapport Therapeutics’ Seizure Drug Surges on Phase II Data
Rapport Therapeutics has reported highly promising Phase II clinical trial results for its experimental epilepsy drug RAP-219, designed to treat drug-resistant focal onset seizures. The open-label...
Lung Cancer Therapeutics: Mixed Phase III and Phase II Trial Updates
Recent data from the International Association for the Study of Lung Cancer highlight mixed outcomes for emerging lung cancer therapies. Summit Therapeutics’ PD-1/VEGF bispecific antibody...
Servier’s Acquisition of Fragile X Syndrome Candidate KER-0193 for $450M
Servier SA has agreed to acquire KER-0193, a novel oral small molecule modulator targeting BK channels for Fragile X Syndrome (FXS), from Kaerus Bioscience for up to $450 million. KER-0193...
Epigenic Therapeutics Raises $60M to Advance CRISPR Epigenetic Therapies
Epigenic Therapeutics Co. Ltd. has closed a $60 million Series B financing round to advance clinical development of gene therapy candidates: EPI-003 for chronic hepatitis B virus (HBV) and EPI-001...
AI Models Predict Long-Term Stability of Biotherapeutic Cell Lines
Researchers at Massachusetts Institute of Technology have developed the first publicly available artificial intelligence model predicting the long-term stability of Chinese Hamster Ovary (CHO)...
David Baltimore, Nobel Laureate and Molecular Biology Pioneer, Dies at 87
David Baltimore, Nobel Prize-winning molecular biologist renowned for his discovery of reverse transcriptase and groundbreaking contributions to cancer and viral research, died at age 87....
RedC Biotech Develops Lab-Grown Universal Blood Supply from Stem Cells
Israeli startup RedC Biotech is pioneering large-scale production of universal donor red blood cells cultivated from stem cells within bioreactors, aiming to alleviate chronic global blood...
Cancer Cells Exploit Alternative Metabolic Pathways to Sustain Growth
Van Andel Institute researchers have uncovered an alternative metabolic route in cancer cells, whereby β-hydroxybutyrate is converted into cytosolic acetyl-CoA, vital for lipid synthesis and cell...